ClinicalTrials.gg
RecruitingNCT05318755CGAHTUpdated Oct 6, 2026

China Gender-affirming Hormone Therapy Study

An observational study in Transgender and Gender Incongruence, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Peking University Third Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Updated Oct 6, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese transgender population. CGAHT is designed to describe the social and mental condition of transgender people who are seeking for formal GAHT, and to investigate the physical and psychological effects of GAHT on this population in China.

Read the detailed description

CGAHT will be conducted in one of the main transgender medical centers in Chinese mainland. Participants who are seeking for the start of GAHT will be enrolled from clinical visitors. Before GAHT, participants will be interviewed with questionaries about their life experience, gender identity and social economic conditions. Evaluations on mental and physical health will be performed at baseline and during the GAHT. Participants will be followed up to 12 months. GAHT will be given to transgender people according to the protocol recommended by the international guideline (doi: 10.1210/jc.2017-01658) .

02

Conditions studied

  • Transgender
  • Gender Incongruence

Browse trials for

Keywords

  • Transgender Persons
  • Gender-affirming Hormone Therapy
03

In context

Gender Dysphoria

85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.

This study's planned enrollment of 240 is above the median of 100 across 52 observational studies indexed under Gender Dysphoria.

Browse Gender Dysphoria studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 275 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

100 transgender men, 100 trangender women, 20 healthy cisgender men and 20 healthy cisgender women

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Transgender men and women
  • Meet criteria of (Fifth Edition) for gender dysphoria
  • Aged between 18 to 40 years
  • People desire to start the GAHT
  • No previous history of gender-affirming interventions
  • Having full ability to make
  • Dextromanual

Exclusion criteria

Exclusion Criteria:

  • Disorders of sex development
  • Who has fertility demand but have not made fertility preservation
  • With contradictions of GAHT
  • Comorbid diseases are not under control
  • Alcohol or drug abuse
  • Hormonal and chromosomal disorders
  • History of gender affirming surgery
  • Current psychiatric disorders
  • History of brain trauma or neurological pathologies
  • Current use of medications with psychotropic effects within two weeks (antipsychotic or antiepileptic agents, lithium, benzodiazepines or opioid analgesics)
  • Claustrophobia
  • Implanted metal and medical devices (pacemakers, ceramic teeth, etc.),
  • Tattoos or eyebrow tattooing (heavy metal dye)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • transgender men

    People whose sex assigned at birth is female but whose self-identified gender is male.

    Drug: GAHT for transgender men

  • transgender women

    People whose sex assigned at birth is male but whose self-identified gender is female.

    Drug: GAHT for transgender women

  • Healthy cisgender people

    People whose sex assigned at birth corresponds with their self-identified gender.

Interventions

  • DrugTestosteroneStudies of TestosteroneTestosterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Testosterone undecanoate

    Also known as: Testosterone

  • DrugGAHT for transgender women

    Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)

    Also known as: Feminizing drugs

06

What researchers measure

Primary outcomes

  1. Change from Baseline Insulin Sensitivity at 12 months

    Insulin sensitivity will be assessed with composite insulin sensitivity index (ISI), which is calculated as 10 000/√\[(fasting glucose \[mg/dL\]) ×(fasting insulin \[μU/mL\]) × (mean glucose \[mg/dL\]) × (mean insulin \[μU/mL\])\], using 0 min, 60 min, and 120 min values of oral glucose tolerance test (OGTT). Composite ISI will be evaluated at baseline and every 6 months until 12 months of GAHT.

    Time frame: 12 months

  2. Change from Baseline Beta-cell Function at 12 months

    Beta-cell function will be assessed with oral glucose tolerance test-derived disposition index (DI). First, 60 min insulinogenic index (IGI60) is calculated as (insulin60 min-insulin0 min\[μU/mL\])/(glucose60 min-glucose0 min \[mmol/L\]), using 0 min and 60 min values of OGTT. Then DI is calculated by multiplying IGI60 with composite ISI to reflect beta-cell function adjusting for the insulin sensitivity. DI will be evaluated at baseline and every 6 months until 12 months of GAHT.

    Time frame: 12 months

  3. Change from Baseline Bone Mineral Density at 12 months

    Bone mineral densities (g/cm\^2) of lumber spine and hip will be evaluated by dual-energy X-ray absorptiometry at baseline and 12 months of GAHT.

    Time frame: 12 months

  4. Depression Changes from Baseline Psychological Questionnaires at 12 months

    Patient Health Questionnaire will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT

    Time frame: 12 months

  5. Anxiety Changes from Baseline Psychological Questionnaires at 12 months

    Generalized anxiety disorder scale will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT

    Time frame: 12 months

  6. Suicide Ideation Changes from Baseline Psychological Questionnaires at 12 months

    Beck scale for suicide ideation will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT

    Time frame: 12 months

  7. Gender Dysphoria Changes from Baseline Psychological Questionnaires at 12 months

    Utrecht gender dysphoria scale will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT

    Time frame: 12 months

  8. Social Exclusion Changes from Baseline at 12 months

    Cyberball task will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT.

    Time frame: 12 months

  9. Functional brain Change after 6 months of GAHT

    Change of functional connectivity will be analyzed to understand at 6 months of GAHT.

    Time frame: 6 months

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    The incidence of adverse events during the 12 months of GAHT will be calculated, including thromboembolic events, drug-induced liver injury, hyperkalemia, newly diagnosed cardiovascular disease, erythrocytosis and newly diagnosed tumor.

    Time frame: Up to 12 months

  2. Change from Baseline Body Mass Index at 12 months

    Body mass index is calculated as \[weight (kg) / height (m)\^2\], which will be evaluated at baseline and every 3 months until 12 months of GAHT.

    Time frame: 12 months

  3. Change from Baseline Waist-hip Ratio at 12 months

    Waist-hip ratio is calculated as \[waist (cm)/hip (cm)\], which will be evaluated at baseline and every 3 months until 12 months of GAHT.

    Time frame: 12 months

  4. Change from Baseline Body Composition at 12 months

    Fat percentage (%) and lean mass (kg) will be assessed using the InBody S10. The body composition will be evaluated at baseline and 12 months of GAHT.

    Time frame: 12 months

  5. Change from Baseline Breast Volume of transgender women at 12 months

    Breasts of transgender women will be shot in 360° with 3D photography. The volume (ml) of both sides will be measured by the image analysis at baseline and every 6 months until 12 months of GAHT.

    Time frame: 12 months

  6. Change from Baseline Homeostatic Model Assessment Index (HOMA-IR) at 12 months

    HOMA-IR is calculated as \[(fasting insulin \[µU/mL\] × fasting glucose \[mmol/L\])/22.5\]. HOMA-IR will be evaluated at baseline and every 6 months until 12 months of GAHT.

    Time frame: 12 months

  7. Change from Baseline Homeostatic Model Assessment of Beta-cell function (HOMA-β) at 12 months

    HOMA-β is calculated as \[20 × (fasting insulin \[μU/mL\]) × (fasting glucose -3·5 \[mmol/L\])\]. HOMA-β will be evaluated at baseline and every 6 months until 12 months of GAHT.

    Time frame: 12 months

  8. Change from Baseline Serum Uric Acid at 12 months

    Serum Uric Acid levels (μmol/l) will be evaluated at baseline and every 3 months until 12 months of GAHT.

    Time frame: 12 months

  9. Comparison of Transgender and Cisgender Functional Brain Patterns

    Functional connectivity will be compared at baseline to understand the brain patterns of transgender.

    Time frame: At baseline

  10. Comparison of Transgender and Cisgender Cognitive Ability

    Performance of mental rotation task of transgender and cisgender will be compared at baseline to understand the difference.

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Dataset is available from the corresponding author on reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Dec 2027, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Apr 8, 2022
StartActual
Apr 16, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Peking University Third Hospital · Beijing, China
Show 1 removed
  • Peking University Third Hospital · Peking, China
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site added, 1 site removed
    Show site
    • Peking University Third Hospital · Beijing, China
    Show 1 removed
    • Peking University Third Hospital · Peking, China
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05318755
Collaborators
Tsinghua University
Responsible party
Hong Tianpei (Professor, Peking University Third Hospital) — Principal investigator
First posted
Apr 8, 2022
Start date
Apr 16, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Ye Liu, PhD., M.D.
Contact
yeliumed@bjmu.edu.cn
+86-10-82265025
Tianpei Hong, M.D.
Contact
tpho66@bjmu.edu.cn
+86-10-82266918
Tianpei Hong, PhD., M.D.
principal investigator · Department of Endocrinology and Metabolism, Peking University Third Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion